Variability in Glycated Hemoglobin and Risk of Poor Outcomes Among People With Type 2 Diabetes in a Large Primary Care Cohort Study
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Diabetes guidelines focus on target glycated hemoglobin (HbA1c) levels. Long-term variability in HbA1c may be predictive of hospitalization or mortality, but its importance at different average levels or trajectories is unclear. RESEARCH DESIGN AND METHODS: Using English primary care data, 58,832 patients with type 2 diabetes had HbA1c average (mean of annual means), variability (coefficient of variation), and trajectory (annual regression slope) estimated during 2006–2009. Hazard ratios (HRs) for mortality and emergency hospitalization during 2010–2015, with adjustment for age, sex, smoking, BMI, duration of diabetes, and deprivation, were estimated using Cox regression. The simultaneous impact of HbA1c average, variability, and trajectory was estimated using percentiles. RESULTS: In mutually adjusted models, HbA1c variability showed a consistent dose-response relationship with all-cause mortality, while average level was only important among individuals in the highest or lowest 10% of the distribution, and trajectory had no independent effect. Individuals with the most unstable HbA1c (top 10%) were almost twice as likely to die (HR 1.93 [95% CI 1.72–2.16]) than were those with the most stable (bottom 10%)—an association attenuated but not explained by hypoglycemia. For emergency hospitalizations, similar trends were seen except for coronary artery disease (CAD) and ischemic stroke (IS), where increasing average rather than variability was predictive. CONCLUSIONS: HbA1c variability was strongly associated with overall mortality and emergency hospitalization and not explained by average HbA1c or hypoglycemic episodes. Only for CAD and IS hospitalizations was no association found, with average HbA1c strongly predictive. Targets should focus on both stability and absolute level of HbA1c.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Data Resource Profile: Clinical Practice Research Datalink (CPRD)
Herrett, E., Gallagher, A. M., Bhaskaran, K., Forbes, H., Mathur, R., van Staa, T., & Smeeth, L. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv098 · Cited by 2,667
Ahlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., Vikman, P., Prasad, R. B., Aly, D. M., Almgren, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30051-2 · Cited by 2,335
Dungan, K. M., Braithwaite, S. S., & Preiser, J.-C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60553-5 · Cited by 1,431
Khaw, K.-T., Wareham, N., Bingham, S., Luben, R., Welch, A., & Day, N. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00006 · Cited by 974 · cited 2×
“IMD combines data from seven domains (income, employment, education skills and training, health and disability, crime, barriers to housing and services, and living environment), ranking local areas from the most deprived (1) to the least deprived (32,884) (25).”
BackgroundData Resource Profile: Hospital Episode Statistics Admitted Patient Care (HES APC)
Herbert, A., Wijlaars, L., Zylbersztejn, A., Cromwell, D., & Hardelid, P. (2017) · International Journal of Epidemiology · doi:10.1093/ije/dyx015 · Cited by 742 · cited 1×
“, emergency), in addition to the primary reason for the admission (24).”
BackgroundGlycaemic variability in diabetes: clinical and therapeutic implications
Ceriello, A., Monnier, L., & Owens, D. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30136-0 · Cited by 588 · cited 2×
“It has thus been hypothesized that longer-term variability in serial HbA1c measurements may also be important (12,13).”
BackgroundLong-term Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review and Meta-analysis
Gorst, C., Kwok, C. S., Aslam, S., Buchan, I., Kontopantelis, E., Myint, P. K., Heatlie, G., Loke, Y., Rutter, M. K., & Mamas, M. A. (2015) · Diabetes Care · doi:10.2337/dc15-1188 · Cited by 530
Glycemic Variability: How Do We Measure It and Why Is It Important?
Suh, S., & Kim, J. H. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.4.273 · Cited by 439
A1C Variability and the Risk of Microvascular Complications in Type 1 Diabetes
Kilpatrick, E. S., Rigby, A. S., & Atkin, S. L. (2008) · Diabetes Care · doi:10.2337/dc08-0864 · Cited by 420
Hemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T., Hemmingsen, C., & Wetterslev, J. (2011) · BMJ · doi:10.1136/bmj.d6898 · Cited by 386 · cited 1×
“control (to ,7% HbA1c [53 mmol/mol]) among individuals with newly diagnosed DM, particularly for microvascular outcomes (3), though benefits for cardiovascular outcomesandall-causemortality has been less clear-cut (5,6).”
Background
Cited by
Glycemic variability: adverse clinical outcomes and how to improve it?
Zhou, Z., Sun, B., Huang, S., Zhu, C., & Bian, M. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01085-6 · Cited by 255
Chen, J., Yi, Q., Wang, Y., Wang, J., Yu, H., Zhang, J., Hu, M., Xu, J., Wu, Z., Hou, L., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110085 · Cited by 69
Kaze, A. D., Santhanam, P., Erqou, S., Ahima, R. S., & Echouffo-Tcheugui, J. B. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001753 · Cited by 40
Cahn, A., Zuker, I., Eilenberg, R., Uziel, M., Tsadok, M. A., Raz, I., & Lutski, M. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3485 · Cited by 9
Metadata
- Authors
- Critchley, J. A., Carey, I. M., Harris, T., DeWilde, S., & Cook, D. G.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-10-03
- Volume
- 42
- Issue
- 12
- Pages
- 2237-2246
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2978865529
- Cited by
- 78
- References
- 14
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.